Sava Infond d.o.o. Purchases New Shares in Natera, Inc. (NASDAQ:NTRA)

Sava Infond d.o.o. bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 4,000 shares of the medical research company's stock, valued at approximately $633,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Blue Trust Inc. grew its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc boosted its stake in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. increased its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares during the period. Finally, True Wealth Design LLC purchased a new stake in shares of Natera in the third quarter worth about $57,000. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 1,026 shares of Natera stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $149,837.04. Following the sale, the insider now directly owns 144,782 shares in the company, valued at approximately $21,143,963.28. This trade represents a 0.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the transaction, the director now owns 9,704 shares of the company's stock, valued at approximately $1,433,183.76. This represents a 29.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 306,797 shares of company stock valued at $48,940,883 over the last ninety days. 7.60% of the stock is owned by insiders.

Remove Ads

Natera Trading Down 3.3 %

NTRA stock traded down $4.68 during midday trading on Monday, hitting $139.26. The company had a trading volume of 703,168 shares, compared to its average volume of 1,362,178. The stock has a market cap of $18.83 billion, a price-to-earnings ratio of -79.35 and a beta of 1.80. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock's 50 day moving average price is $159.60 and its 200 day moving average price is $151.13.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Royal Bank of Canada started coverage on Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. Robert W. Baird boosted their price objective on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Guggenheim upped their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, January 17th. JPMorgan Chase & Co. lifted their target price on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Finally, The Goldman Sachs Group increased their price target on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.